I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2018 through 2027 and % CAGR

Table 2: World Historic Review for Preclinical Imaging
(In-VIVO) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2017 and % CAGR

Table 3: World 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets for Years 2012, 2018 & 2027

Table 4: World Current & Future Analysis for Preclinical
imaging modalities by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2018 through 2027 and % CAGR

Table 5: World Historic Review for Preclinical imaging
modalities by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2017 and % CAGR

Table 6: World 15-Year Perspective for Preclinical imaging
modalities by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2018 & 2027

Table 7: World Current & Future Analysis for Preclinical
imaging reagents by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2018 through 2027 and % CAGR

Table 8: World Historic Review for Preclinical imaging reagents
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2017 and
% CAGR

Table 9: World 15-Year Perspective for Preclinical imaging
reagents by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 10: USA Current & Future Analysis for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2018 through 2027 and %
CAGR

Table 11: USA Historic Review for Preclinical Imaging (In-VIVO)
by Segment - Preclinical imaging modalities and Preclinical
imaging reagents Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2017 and % CAGR

Table 12: USA 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

CANADA
Table 13: Canada Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2018 through 2027
and % CAGR

Table 14: Canada Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2017 and %
CAGR

Table 15: Canada 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

JAPAN
Table 16: Japan Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2018 through 2027
and % CAGR

Table 17: Japan Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2017 and %
CAGR

Table 18: Japan 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

CHINA
Table 19: China Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2018 through 2027
and % CAGR

Table 20: China Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2017 and %
CAGR

Table 21: China 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

EUROPE
Table 22: Europe Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2018 through 2027 and %
CAGR

Table 23: Europe Historic Review for Preclinical Imaging
(In-VIVO) by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2017 and % CAGR

Table 24: Europe 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2012, 2018 & 2027

Table 25: Europe Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2018 through 2027
and % CAGR

Table 26: Europe Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2017 and %
CAGR

Table 27: Europe 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

FRANCE
Table 28: France Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2018 through 2027
and % CAGR

Table 29: France Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2017 and %
CAGR

Table 30: France 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

GERMANY
Table 31: Germany Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2018 through 2027
and % CAGR

Table 32: Germany Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2017 and %
CAGR

Table 33: Germany 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

ITALY
Table 34: Italy Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2018 through 2027
and % CAGR

Table 35: Italy Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2017 and %
CAGR

Table 36: Italy 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

UNITED KINGDOM
Table 37: UK Current & Future Analysis for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2018 through 2027 and %
CAGR

Table 38: UK Historic Review for Preclinical Imaging (In-VIVO)
by Segment - Preclinical imaging modalities and Preclinical
imaging reagents Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2017 and % CAGR

Table 39: UK 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

REST OF EUROPE
Table 40: Rest of Europe Current & Future Analysis for
Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging
modalities and Preclinical imaging reagents - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2018
through 2027 and % CAGR

Table 41: Rest of Europe Historic Review for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2017 and
% CAGR

Table 42: Rest of Europe 15-Year Perspective for Preclinical
Imaging (In-VIVO) by Segment - Percentage Breakdown of Value
Sales for Preclinical imaging modalities and Preclinical
imaging reagents for the Years 2012, 2018 & 2027

ASIA-PACIFIC
Table 43: Asia-Pacific Current & Future Analysis for
Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging
modalities and Preclinical imaging reagents - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2018
through 2027 and % CAGR

Table 44: Asia-Pacific Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2017 and %
CAGR

Table 45: Asia-Pacific 15-Year Perspective for Preclinical
Imaging (In-VIVO) by Segment - Percentage Breakdown of Value
Sales for Preclinical imaging modalities and Preclinical
imaging reagents for the Years 2012, 2018 & 2027

REST OF WORLD
Table 46: Rest of World Current & Future Analysis for
Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging
modalities and Preclinical imaging reagents - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2018
through 2027 and % CAGR

Table 47: Rest of World Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2017 and %
CAGR

Table 48: Rest of World 15-Year Perspective for Preclinical
Imaging (In-VIVO) by Segment - Percentage Breakdown of Value
Sales for Preclinical imaging modalities and Preclinical
imaging reagents for the Years 2012, 2018 & 2027

IV. COMPETITION
Total Companies Profiled: 38